Debora Fumagalli

2161 POSTER INTEGRATE: Driving Excellence in Integrative Cancer Research Through Innovative Biomedical Infrastructures

Christine Desmedt, Christos Sotiriou, Anca I. D. Bucur, 2011 .

Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome

David Gacquer, Peter J. Campbell, Christine Desmedt, 2015, bioRxiv.

Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.

Debora Fumagalli, Norman Wolmark, Soonmyung Paik, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value

Greg Yothers, Hyun Joo Choi, Debora Fumagalli, 2012, Clinical Cancer Research.

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

Jong-Hyeon Jeong, Hanna Bandos, Debora Fumagalli, 2013, Journal of the National Cancer Institute.

Molecular Profiling: Moving Away from Tumor Philately

Jorge S. Reis-Filho, Christos Sotiriou, Debora Fumagalli, 2010, Science Translational Medicine.

Luminal B breast cancer: molecular characterization, clinical management, and future perspectives.

Christos Sotiriou, Debora Fumagalli, C. Sotiriou, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

No significant viral transcription detected in whole breast cancer transcriptomes

David Gacquer, Christos Sotiriou, Debora Fumagalli, 2015, BMC Cancer.